Repligen (RGEN) Announces CEO Transition Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Repligen Announces CEO Transition Plan
June 13, 2024 7:00 AM EDTWALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (Board) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (CEO) to Executive Chair, effective September 1, 2024. The Companys Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current... More
